Congenital generalized lipodystrophy (CGL), also known as Berardinelli-Seip syndrome (BSS), is a rare autosomal recessive disease characterized by near total absence of adipose tissue and muscular hypertrophy. Additional common clinical signs are acanthosis nigricans, acromegaloid features, hepatomegaly, hyperandrogenism, altered glucose intolerance, cardiomyopathy and hypertriglyceridemia. An 11-year-old girl was admitted to our Clinic presenting with hyperandrogenic features, generalized lack of adipose tissue, generalized muscular hypertrophy and brownish colored skin on the neck, axillas and inguinal folds associated with impaired glucose tolerance and hypertension. A clinical diagnosis of congenital generalized lipodystrophy was made.
1. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta. 2009;1791(6):507–3.
2. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59(1):16-23.
3. Abate N. Adipocyte maturation arrest: a determinant of systemic insulin resistance to glucose disposal. J Clin Endocrinol Metab. 2012;97(3):760–3.
4. Bertrand AT, Chikhaoui K, Ben Yaou R, Bonne G. [Laminopathies: one gene, several diseases]. Biol Aujourdhui. 2011;205(3):147–62.
5. Bissonnette B, Luginbuehl I, Marciniak B, Dalens B. Syndromes: rapid recognition and perioperative imlications. New York: McGraw-Hill; 2006.
6. Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr, Van Maldergem L, Sobel E, et al. Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28(4):365–70.
7. Magre J, Delepine M, Van Maldergem L, Robert JJ, Maassen JA, Meiser M, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52(6):1573–8.
8. Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O’Rahilly S, et al. Phenotypic and genetic heterogenecity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003;88(10):4840–7.
9. Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab. 1954;14(2):3390-4.
10. Seip M. Lipodystrophy and gigantism with associated endocrine manifestations: a new diencephalic syndrome? Acta Pediatr. 1959;48:555-74.
11. Van Maldergem L, Magre J, Khallouf TE, Gedde-Dahl T Jr, Delepine M, Trygstad O, et al. Genotype–phenotype relationships in Berardinelli–Seip congenital lipodystrophy. J Med Genet. 2002;39(10):722–33.
12. Roth DE, Schikler KN, Callen JP. Annular atrophic connective tissue panniculitis of the ankles. J Am Acad Dermatol. 1989;21(5 Pt 2):1152-6.
13. Bennett T, Allford M. Delayed emergence from anesthesia in a child with congenital generalized lipodystrophy (Berardinelli-Seip syndrome). Paediatr Anaesth. 2012;22(3):298-313.
14. Pardini VC, Victoria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab. 1998;83(2):503–8.
15. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513-9.
16. Gorden P, Gavrilova O. The clinical uses of leptin. Curr Opin Pharmacol. 2003;3(6):655-9.